Clinical trial
An Exploratory Study of Vedotin-tislelizumab Combined With Toripalimab in EGFR-positive Refractory Advanced Biliary Tract Malignancies
NCT07472933 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Study of Vedotin-tislelizumab Combined With Toripalimab in EGFR-positive Refractory Advanced Biliary Tract Malignancies
- Lead sponsor
- West China Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- August 1, 2026
- Completion date
- February 29, 2028
- Enrollment
- 49 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cancer of biliary duct